
Oncolytics Biotech Inc. (NASDAQ:ONCY – Free Report) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Oncolytics Biotech in a research note issued to investors on Thursday, November 19th. HC Wainwright analyst P. Trucchio expects that the company will earn $0.01 per share for the year. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.30) per share.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last released its earnings results on Friday, November 13th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03).
Check Out Our Latest Report on ONCY
Oncolytics Biotech Price Performance
Shares of NASDAQ:ONCY opened at $0.35 on Friday. The company has a market cap of $47.66 million, a PE ratio of -1.09 and a beta of 1.26. The stock’s 50-day moving average is $0.54 and its 200 day moving average is $0.81. Oncolytics Biotech has a 1 year low of $0.33 and a 1 year high of $1.30.
Hedge Funds Weigh In On Oncolytics Biotech
Large investors have recently added to or reduced their stakes in the company. Renaissance Technologies LLC purchased a new stake in shares of Oncolytics Biotech in the first quarter worth $608,000. International Assets Investment Management LLC lifted its stake in shares of Oncolytics Biotech by 129.6% during the 3rd quarter. International Assets Investment Management LLC now owns 462,008 shares of the company’s stock valued at $310,000 after buying an additional 260,748 shares in the last quarter. Connective Capital Management LLC purchased a new position in shares of Oncolytics Biotech during the 2nd quarter valued at $176,000. Susquehanna International Group LLP boosted its holdings in Oncolytics Biotech by 224.6% in the 2nd quarter. Susquehanna International Group LLP now owns 134,129 shares of the company’s stock worth $127,000 after buying an additional 92,806 shares during the period. Finally, Fifth Third Bancorp boosted its holdings in Oncolytics Biotech by 87.9% in the 3rd quarter. Fifth Third Bancorp now owns 85,526 shares of the company’s stock worth $57,000 after buying an additional 40,000 shares during the period. Hedge funds and other institutional investors own 6.82% of the company’s stock.
Recent Oncolytics Biotech Headlines
Here are a few of the latest headlines about ONCY:
- Positive Sentiment: HC Wainwright raised its EPS forecasts for 2026–2029, projecting narrower losses, and maintained its Buy rating. This is a modestly positive analyst signal. HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech
- Negative Sentiment: Zacks Research lowered its estimates for 2026–2028, including a wider projected FY2026 loss of $0.31 per share versus its prior $0.27 estimate. The more cautious outlook tempers HC Wainwright’s revisions. Oncolytics Biotech analyst estimates
Oncolytics Biotech Company Profile
Oncolytics Biotech is a clinical-stage biotechnology company developing cancer immunotherapies. Its lead product candidate, pelareorep, is an investigational virus-based therapy intended to activate the immune system against cancer. The company is studying pelareorep in combination with other treatments, including chemotherapy and immunotherapies, for cancers such as breast cancer and pancreatic cancer. Pelareorep is not an approved treatment. Based in Canada, Oncolytics conducts clinical development through research and trials involving patients and collaborators in multiple regions.
See Also
- Five stocks we like better than Oncolytics Biotech
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
